MachuPicchu schreef op 9 juli 2020 15:36:
[...]
endpts.com/gilead-bolsters-its-case-f..."While such class labeling does limit Rinvoq's commercial opportunity, we now expect the whole JAK class, including the much-anticipated 'safer JAK inhibitor' filgotinib, to receive similar labeling," Porges wrote in a Sunday research note.
maar dan schrijven ze ook nog;
All three also have black box warnings, the FDA's strictest possible warning. While Xeljanz and Olumiant both featured warnings specific to those drugs, Rinvoq's warning included a
more general description of the thrombotic risks.
Dus bloedproppen of algemene omschrijving, het kan allemaal. Hieruit kun je al bijna opmaken dat een BBW komt. Alleen al dat de FDA zich vrij pleit.